Modulation of lipoprotein metabolism by antisense technology: Preclinical drug discovery methodology

Methods in Molecular Biology

Volumn 1027, Issue , 2013, Pages 309-324

  Crooke, Rosanne M ^a   Graham, Mark J ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

2 O 2 methoxyethyl (2 MOE) antisense oligonucleotides (ASOs); Acetyl coenzyme A carboxylases 1 and 2 (ACC1, ACC2); Acyl coenzyme A:cholesterol acyltransferase 2 (ACAT2); Antisense technology; Apolipoprotein B 100; Apolipoprotein C III; Apolipoprotein(a); Diacylglycerol acyltransferase 2 (DGAT2); High density lipoprotein cholesterol (HDL C); Lipoprotein metabolism; Lipoprotein(a); Low density lipoprotein cholesterol (LDL C); RNase H; Stearoyl CoA desaturase 1 (SCD 1); Triglycerides (TG); Very low density lipoprotein cholesterol (VLDL C)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; MESSENGER RNA; MIPOMERSEN; RIBONUCLEASE H; RNA PRECURSOR;

ARTICLE; CLINICAL TRIAL; COMPUTER MODEL; HUMAN; HYPERLIPIDEMIA; IC 50; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA SEQUENCE; SINGLE DRUG DOSE; CHEMISTRY; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; RNA STABILITY;

DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOPROTEINS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA PRECURSORS; RNA STABILITY; RNA, MESSENGER;

EID: 84922773672     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-369-5_14     Document Type: Article

References (91)

1. Crooke ST (2004) Progress in antisense technology. Annu Rev Med 55:61-95
2. Crooke ST (1999) Molecular mechanism of action of antisense drugs. Biochim Biophys Acta 1489:31-44
3. Crooke ST (1998) Molecular mechanisms of antisense drugs: RNaseH. Antisense Nucleic Acid Drug Dev 8:133-134
4. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST (2004) Determination of the role of the human RNAse H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279:17181-17189
5. Lima W, Rose JB, Nichols JG, Wu H, Migawa MT, Wyrzykiewicz TK, Vasques G, Swayze EE, Crooke ST (2007) The positional in fl uence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol Pharmacol 71:73-82
6. Lima W, Rose JB, Nichols JG, Wu H, Migawa MT, Wyrzykiewicz TK, Siwkowski AM, Crooke ST (2007) Human RNaseH1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol 71:83-91
7. Lima W, Wu H, Crooke ST (2008) The RNase H mechanism. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 47-74
8. Henry SP, Geary RS, Yu R, Levin AA (2001) Drug properties of second generation antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Invest Drugs 2:1444-1449
9. Dean NM, Butler M, Monia BP, Manoharan M (2001) Pharmacology of 2 ¢ -O-(2-methoxyethyl) Modified antisense oligonucleotides. In: Crooke ST (ed) Antisense technology: Principles, strategies and applications. Marcel Dekker, Inc., New York, NY, pp 319-338
10. Zellweger T, Miyake H, Cooper S, Conklin BS, Monia BP, Gleave ME (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2 ¢ -O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934-940
11. Kastelein JJP, Wedel MW, Baker BB, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM (2006) Potent reduction of apolipoprotein B and low density lipoprotein cholesterol by short term administration of an antisense inhibitor of apolipoprotein B. Circulation 114:1729-1735
12. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46:872-884
13. Crooke RM (2005) Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 5:907-917
14. Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nature 5:468-479
15. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA (2002) Phase I trial of ISIS 104838, a 2 ¢ methoxyethyl Modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343
16. Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, Burckin T, Troung L, Sasmor H, Levin AA (2001) Absolute bioavailability of 2 ¢ -O-2-(methoxyethyl)-Modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 296:898-904
17. Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-Defalco C, Geary RS, Monia BP, Karras JG, Gregory SA (2007) Inhaled CD86 antisense oligonucleotide suppresses pulmonary in fl ammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther 321:938-946
18. Miner PB Jr, Geary RS, Matson J, Chuan E, Xia SM, Baker BF, Wedel MK (2006) Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 23:1427-1434
19. Zhang RW, Iyer RP, Yu D, Tan WT, Zhang XZ, Lu ZH, Zhao H, Agrawal S (1996) Pharmacokinetics and tissue disposition of chimeric oligodeoxynucleoside phosphorothioates in rats after intravenous administration. J Pharmacol Exp Ther 278:971-979
20. Hardee GE, Tillman LG, Geary RS (2008) Routes and formulations for delivery of antisense oligonucleotides. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 217-236
21. Henry SP, Kim T-W, Kramer-Strickland K, Zanardi TA, Fey RA, Levin AA (2008) Toxicologic properties of phosphorothioate 2 ¢ -methoxyethyl chimeric antisense inhibitors in animals and man. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 327-363
22. Henry SP, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF (2000) Chemically Modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292:468-479
23. Kwoh JT (2008) An overview of the clinical safety experience of first and second generation oligonucleotides. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 365-399
24. Geary RS, Bradley JD, Watanabe T, Kwon Y, Wedel M, van Lier JJ, VanVliet AA (2006) Lack of pharmacokinetic interaction for ISIS 113715, a 2 ¢ -O-methoxyethyl Modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 45:789-801
25. Geary RS, Yu RZ, Siwkowski A, Levin AA (2008) Pharmacokinetic/ pharmacodynamic properties of phosphorothioate 2 ¢ -O -(2-methoxyethyl)- Modified antisense oligonucleotides in animals and man. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 236-305
26. Kane JP, Havel RJ (2001) Introduction: Structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2705-2716
27. Mahley RW, Bersott TP (2006) Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL (ed) Goodman and Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 933-966
28. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF, Wolf PA, Levy D (2006) Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113:791-798
29. Epstein JA, Rader DJ, Parmacek MS (2002) Perspective: Cardiovascular disease in the postgenomic era-lessons learned and challenges ahead. Endocrinology 143:2045-2050
30. Davis RA, Hui TY (2001) 2000 George Lyman Duff memorial lecture. Atherosclerosis is a liver disease of the heart. Arterioscler Thromb Vasc Biol 21:887-898
31. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349:60-72
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
33. Grundy SM, Cleeman JI, Bairey CN, Brewer HB, Clark LT, Hunninhake D, Pasternak RC, Smith SC, Sone NJ, Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110:227-239
34. Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341:498-511
35. (1998) LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1339-1357
36. Downs GR, Clear fi eld M, Weiss S (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/ TEXCAPS (Air Forces/Texas Coronary Atherosclerosis Prevention Study). JAMA 279:1615-1622
37. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomized placebo controlled trial. Lancet 360:7-22
38. Olofsson S-O, Boren J (2005) Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 258:395-410
39. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S (2008) Antisense oligonucleotide directed to human apolipoprotein-B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118:743-753
40. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Kornman KS, Witztum JL, Berger PB (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353:46-57
41. Annurad E, Boffa MB, Koschinsky ML (2006) Lipoprotein(a): A unique risk factor for cardiovascular disease. Clin Lab Med 26: 751-772
42. Bobik A (2008) Apolipoprotein CIII and atherosclerosis: Beyond effects on lipid metabolism. Circulation 118:702-704
43. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M (2008) Apolipoprotein CIII links hyperlipidemia with vascular cell dysfunction. Circulation 118:731-742
44. Scheffer PG, Teerlink T, Dekker JM, Bos G, Dijpels G, Diamant M, Kostense PJ, Stehouwer CD, Heine RJ (2008) Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: The Hoorn Study. Clin Chem 54:1325-1330
45. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, DAI Study Group (2008) Recurrence of cardiovascular events in patients with type 2 diabetes: Epidemiology and risk factors. Diabetes Care 31(11):2154-2159
46. Mitka M (2004) Guidelines: New lows for LDL target levels. JAMA 292:911-913
47. Rubins HB (2000) Triglycerides and coronary heart disease: Implications of recent clinical trials. J Cardiovasc Risk 7:339-345
48. Watts GF, Barrett PH, Chan DC (2008) HDL metabolism in context: Looking on the bright side. Curr Opin Lipidol 19:395-404
49. deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels. Evaluating high-density lipoprotein function as in fl uenced by novel therapeutic approaches. J Am Coll Cardiol 51:2199-2211
50. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probst fi eld J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, INTERHEART Study Investigators (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case controlled study. Lancet 372:224-233
51. Romero-Corral A, Somers VK, Lopez-Jimenez F (2008) Apolipoproteins: Promising biomarkers for cardiovascular risk prediction. J Intern Med 264:1-3
52. El Harchaoui K, Akdim F, Stroes ES, Trip MD, Kastelein JJ (2008) Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins. Am J Cardiovasc Drugs 8:233-242
53. Athyros VG, Kaka fi ka AI, Tziomalos K, Karagiannis A, Mihkailidis DP (2008) Antisense technology for the prevention or treatment of cardiovascular disease: The next blockbuster? Expert Opin Investig Drugs 17:969-972
54. Ito MK (2007) ISIS 301012 gene therapy for hypercholesterolemia: Sense, antisense, or nonsense? Ann Pharmacother 41:1669-1678
55. Burnett JR (2006) Drug evaluation: ISIS 31012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 8:461-467
56. Crooke ST, Vickers T, Lima W, Hongjiang W (2008) Mechanisms of antisense drug action, an introduction. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 3-46
57. Bennett CF (2002) Ef fi ciency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev 12:215-224
58. Dean NM, Bennett CF (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22:9087-9096
59. Freier SM, Watt AT (2008) Basic principles of antisense drug discovery. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 117-141
60. Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5:468-479
61. Bennett CF (2008) Pharmacological properties of 2 ¢ -O -methoxyethyl-Modified oligonucleotides. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 273-303
62. Swayze EE, Bhat B (2008) The medicinal chemistry of oligonucleotides. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 143-182
63. Monia BP, Yu RZ, Lima W, Siwkowski A (2008) Optimization of second-generation antisense drugs: Going beyond generation 2.0. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 487-506
64. Crooke R, Baker B, Wedel M (2008) Cardiovascular therapeutic applications. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 601-639
65. Bell TA, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, Rudel LL (2006) Liverspecific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 26:1814-1820
66. Brown JM, Bell TA, Alger HM, Sawyer JK, Smith TL, Kelley K, Shah R, Wilson MD, Davis MA, Lee RG, Graham MJ, Crooke RM (2008) Targeted depletion of hepatic ACAT2-driven cholesterol esteri fication reveals a nonbiliary route for fecal neutral sterol loss. J Biol Chem 283:10522-10534
67. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM (2007) Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48:763-767
68. Zhang YL, Hernandez-Ono A, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN (2006) Aberrant hepatic expression of PPAR g 2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia and hepatic steatosis. J Biol Chem 281:37603-37615
69. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS (2007) Reduction of hepatosteatosis and lipid levels by an adipose differentiation- related protein antisense oligonucleotide. Gastroenterology 132:1947-1954
70. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA (2003) Pharmacokinetics of a tumor necrosis factor alpha phosphorothioate 2 ¢ -O-(2-methoxyethyl) Modified antisense oligonucleotide: Comparison across species. Drug Metab Dispos 31:1419-1428
71. Geary RS, Watanabe TA, Truong L, Freier SA, Lesnik EA, Siou fi NB, Sasmor H, Manoharan M, Levin AA (2001) Pharmacokinetic properties of 2 ¢ -O-(2-methoxyethyl)-Modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897
72. Yu R, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA (2004) Tissue disposition of 2 ¢ -O-(2-methoxyethyl)-Modified oligonucleotides in monkeys. J Pharm Sci 93:48-59
73. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403-410
74. Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Cice VC (2004) Advanced transfection with Lipofectamine 2000 reagent: Primary neurons, siRNA, and high-throughput applications. Methods 33:95-103
75. Nolan T, Hands RE, Bustin SA (2006) Quanti fication of mRNA using real-time RT-CR. Nat Protoc 1:1559-1582
76. Bustin SA (2000) Absolute quanti fication of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169-193
77. Alwine JC, Kemp DJ, Stark GR (1977) Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl paper and hybridization with DNA probes. Proc Natl Acad Sci U S A 12:5350-5354
78. deFougerolles AR, Maraganore JM (2008) Discovery and development of RNAi therapeutics. In: Crooke ST (ed) Antisense drug technology. Principles, strategies and applications. CRC, Boca Raton, FL, pp 465-484
79. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Manoharan M, Vornlocher HP (2004) Therapeutic silencing of an endogenous gene by systemic administration of Modified siRNAs. Nature 432:173-178
80. Krause BR, Princen HMG (1998) Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice? Atherosclerosis 140:15-24
81. Zadelaar S, Kleeman R, Verschuren L, deVries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T (2007) Mouse models for atherosclerosis and pharmaceutical modi fiers. Arterioscler Thromb Vasc Biol 27:1706-1721
82. Grass DS, Saini U, Felkner RH, Wallace RE, Lao WJ, Young SG, Swanson ME (1995) Transgenic mice expressing both human apolipoprotein B and human CETP have a similar lipoprotein cholesterol distribution similar to that of normolipidemic humans. J Lipid Res 36:1082-1091
83. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113:90-97
84. Arai T, Wang N, Bezouevski M, Welch C, Tall AR (1999) Decreased atherosclerosis in heterozygous low density lipoprotein receptordeficient mice expressing the scavenger receptor B1 transgene. J Biol Chem 274:2366-2371
85. Mullick AE, Graham MJ, Fu W, York-DeFalco C, Crooke RM (2008) Antisense inhibition of apolipoprotein B ameliorated diet-induced hypercholesterolemia and reduced atherosclerosis in LDL receptor-deficient mice. Arteriosclerosis, Thrombosis and Vascular Biology 2008 Annual Conference, Atlanta, GA, p 345, 16-18 April
86. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ Jr (2003) CP-346086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and humans. J Lipid Res 44:1887-1901
87. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarlis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ (2007) Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356:148-156
88. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL et al (2008) Newly identi fied loci that in fl uence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161-169
89. Breslow JL (2000) Genetics of lipoprotein abnormalities associated with coronary heart disease susceptibility. Annu Rev Genet 34:233-254
90. Lunetta KL, D'Agostino RB, Karasik D, Benjamin EJ, Gui CY, Govindaraju R, Kiel DP, Kelly-Hayes M, Massaro JM, Pencina MJ, Seshadri S, Murabito JM (2007) Genetic correlates of longevity and selected age-related phenotypes: A genome-wide association study in the Framingham Study. BMC Med Genet 19:8(Suppl 1):S13
91. Holleboom AG, Vergeer M, Hovingh GK, Kastelein JJP, Kuivenhoven JA (2008) The value of HDL genetics. Curr Opin Lipidol 19:385-394